A Study to Demonstrate Bioequivalence Between Semaglutide Drug Product Concentrations 0.68 mg/mL and 1.34 mg/mL
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 03 Jul 2023 Status changed from recruiting to completed.
- 02 Feb 2023 Status changed from not yet recruiting to recruiting.
- 20 Jan 2023 New trial record